Next 10 |
home / stock / sybx / sybx articles
Synlogic Inc (NASDAQ:SYBX) shares are trading lower by 48.4% to $1.78 Friday afternoon after the company announced it will discontinue Synpheny-3, ...
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 1% on Friday. The Dow traded down 0.09% to 38,69...
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results. Take-Two...
Thursday, Synlogic Inc (NASDAQ:SYBX) announced its decision to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselec...
U.S. stocks traded mixed this morning, with the S&P 500 topping the 5,000 mark on Friday. Following the market opening Friday, the Dow traded d...
Shares of Cloudflare, Inc. (NYSE: NET) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-qua...
CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, ...
- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degrada...
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update. In March 2024, t...
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023. The Company...